Table 1.
Patient and treatment characteristics.
| Characteristic | Total (n = 410) |
TNBC(n = 111) |
HR positive (n = 299) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HER2-zero n = 117 | HER2-low n = 293 | P | HER2-zero n = 40 | HER2-low n = 71 | P | HER2-zero n = 77 | HER2-low n = 222 | P | |
| Age（years, median） | 47 | 47 | – | 51 | 50 | – | 45 | 46 | – |
| Histology type | 0.716 | 0.936 | 0.627 | ||||||
| IBC-NST | 98 (83.8) | 241 (82.3) | 33 (82.5) | 59 (83.1) | 65 (84.4) | 182 (82.0) | |||
| Other | 19 (16.2) | 52 (17.7) | 7 (17.5) | 12 (16.9) | 12 (15.6) | 40 (18.0) | |||
| cT | 0.324 | 0.269 | 0.047 | ||||||
| T1-2 | 76 (65.0) | 205 (70.0) | 31 (77.5) | 48 (67.6) | 45 (58.4) | 157 (70.7) | |||
| T3-4 | 41 (35.0) | 88 (30.0) | 9 (22.5) | 23 (32.4) | 32 (41.6) | 65 (29.3) | |||
| cN | 0.369 | 0.069 | 0.014 | ||||||
| N0-1 | 63 (53.8) | 172 (58.7) | 30 (75.0) | 41 (57.7) | 33 (42.9) | 131 (59.0) | |||
| N2-3 | 54 (46.2) | 121 (41.3) | 10 (25.0) | 30 (42.3) | 44 (57.1) | 91 (41.0) | |||
| Clinical stage | 0.292 | 0.012 | 0.003 | ||||||
| II | 48 (41.0) | 137 (46.8) | 24 (60.0) | 25 (35.2) | 24 (31.2) | 112 (50.5) | |||
| III | 69 (59.0) | 156 (53.2) | 16 (40.0) | 46 (64.8) | 53 (68.8) | 110 (49.5) | |||
| HR | 0.040 | – | – | ||||||
| Positive | 77 (65.8) | 222 (75.8) | 0 (0) | 0 (0) | 77 (100.0) | 222 (100.0) | |||
| Negative | 40 (34.2) | 71 (24.2) | 40 (100.0) | 71 (100.0) | 0 (0) | 0 (0) | |||
| Ki-67 | 0.536 | 0.363 | 0.484 | ||||||
| ≤ 30 % | 25 (21.4) | 71 (24.2) | 5 (12.5) | 4 (5.6) | 20 (26.0) | 67 (30.2) | |||
| >30 % | 92 (78.6) | 222 (75.8) | 35 (87.5) | 67 (94.4) | 57 (74.0) | 155 (69.8) | |||
| Chemotherapy regimen | 0.189 | 0.254 | 0.542 | ||||||
| Anthracycline + taxane | 110 (94.0) | 283 (96.6) | 35 (87.5) | 66 (93.0) | 75 (97.4) | 217 (97.7) | |||
| Platinum | 2 (1.7) | 6 (2.0) | 2 (5.0) | 4 (5.6) | 0 (0) | 2 (0.9) | |||
| Others | 5 (4.3) | 4 (1.4) | 3 (7.5) | 1 (1.4) | 2 (2.6) | 3 (1.4) | |||
| Surgery | 0.901 | 0.098 | 0.416 | ||||||
| Mastectomy | 97 (82.9) | 238 (81.2) | 38 (95.0) | 58 (81.7) | 59 (76.6) | 180 (81.1) | |||
| Breast conserving | 14 (12.0) | 40 (13.7) | 2 (5.0) | 7 (9.9) | 12 (15.6) | 33 (14.9) | |||
| IBR | 6 (5.1) | 15 (5.1) | 0 (0) | 6 (8.5) | 6 (7.8) | 9 (4.1) | |||
IBC-NST, invasive breast cancer, no special type; HR, estrogen receptor; IBR, immediate breast reconstruction.